SOP for Global Regulatory News Screening and Triage


Regulatory Affairs: SOP for Global Regulatory News Screening and Triage – V 1.0

Standard Operating Procedure for Global Regulatory News Screening and Triage

Department Regulatory Affairs
SOP No. RA/2026/635
Supersedes NA
Page No. 1 of X
Issue Date 09/04/2026
Effective Date 09/04/2026
Review Date 09/04/2028

Purpose

This Standard Operating Procedure (SOP) defines the systematic approach for the screening, evaluation, and triage of global regulatory news relevant to the company’s products, market authorizations, and regulatory compliance obligations. The objective is to ensure timely identification, assessment, and dissemination of critical regulatory intelligence, supporting informed decision-making and proactive compliance within the Regulatory Affairs function.

Scope

This SOP applies to all Regulatory Affairs personnel involved in monitoring global regulatory news sources, including regulatory authority updates, guidance documents, safety alerts, and policy changes. It covers regulatory news related to all therapeutic areas, dosage forms, processes, and regions where the company operates or markets products. This SOP excludes internal communications unrelated to external regulatory intelligence and does not cover the assessment of company-specific regulatory submissions or approvals.

Responsibilities

  • Regulatory Intelligence Analysts: Conduct daily screening of regulatory news sources, document findings, and perform initial triage.
  • Regulatory Affairs Specialists: Evaluate relevance and impact of screened news on company products and operations.
  • Regulatory Affairs Manager: Review triaged information, provide guidance for required actions, and ensure communication to stakeholders.
  • Quality Assurance: Monitor adherence to this SOP and verify documentation completeness.
  • Documentation Control Personnel: Maintain the controlled repository of regulatory intelligence records.
See also  SOP for Access Control to Regulatory Submission Records

Accountability

The Head of Regulatory Affairs is accountable for the overall implementation, compliance, regular review, escalation of critical regulatory issues, and assessment of the effectiveness of this SOP. They ensure resources and training are adequate to support the global regulatory news screening and triage process.

Procedure

1. Preparation and Prerequisites: Regulatory Intelligence Analysts shall ensure access to all subscribed global regulatory news databases, official regulatory agency websites, and alert services prior to commencing daily screening. Necessary login credentials and subscriptions should be maintained and regularly updated.

2. Daily Screening: Analysts shall perform a thorough review of all relevant news sources using automated alerts and manual checks. This includes global regulatory agencies (e.g., FDA, EMA, PMDA, Health Canada), industry forums, and newsletters. Each news item must be documented with date, source, summary, and potential impact.

3. Initial Triage and Categorization: The analyst shall classify news as critical, moderate, or informational based on predefined criteria such as product impact, regulatory deadlines, or compliance concerns. Items classified as critical or moderate should be flagged for immediate evaluation.

4. Evaluation: Regulatory Affairs Specialists review the triaged news to assess implications on existing marketing authorizations, product labeling, manufacturing processes, or compliance requirements. Risk assessment and recommendations for actions (e.g., internal alerts, updates to SOPs, submission requirements) shall be documented.

5. Communication and Escalation: The Regulatory Affairs Manager shall consolidate evaluated news and coordinate dissemination to relevant departments such as Quality, Manufacturing, or Safety. Critical issues must be escalated promptly with documented rationale and suggested next steps.

6. Documentation: All screening records, triage decisions, evaluations, and communications shall be maintained in a controlled electronic repository. Backup copies must be secured according to company policy. Records retention shall comply with regulatory requirements and company standards.

7. Review and Continuous Improvement: Periodic audits shall be conducted by Quality Assurance to ensure SOP adherence, accuracy of triage, and timely communication. Findings will be reported to the Head of Regulatory Affairs for corrective action and SOP updates.

See also  SOP for Qualification of Regulatory Affairs Personnel

8. Training: All involved personnel shall receive initial and refresher training on this SOP and relevant regulatory intelligence tools. Training records shall be maintained as per company procedures.

This procedure ensures a consistent, reliable, and compliant process to manage global regulatory news, supporting proactive regulatory compliance and risk mitigation.

Abbreviations

  • FDA: Food and Drug Administration
  • EMA: European Medicines Agency
  • PMDA: Pharmaceuticals and Medical Devices Agency
  • QA: Quality Assurance
  • RA: Regulatory Affairs
  • SOP: Standard Operating Procedure
  • GMP: Good Manufacturing Practice

Documents

  1. Global Regulatory News Screening Log (Annexure-1)
  2. Regulatory News Triage Assessment Form (Annexure-2)
  3. Communication Template for Regulatory News Dissemination (Annexure-3)

References

  • FDA Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
  • EMA Management of Regulatory Intelligence Guidelines
  • ICH Q10 Pharmaceutical Quality System
  • ISO 9001: Quality Management Systems Requirements
  • Company Quality Manual and Regulatory Affairs Policies

Version

1.0

Approval

Prepared By
Checked By
Approved By

Annexures

Annexure-1: Global Regulatory News Screening Log

Purpose: To systematically document all regulatory news items screened daily, including source, summary, date, and initial triage categorization.

Date Source Summary Triage Category Comments
08/04/2026 FDA Website Release of new guidance on anti-infective drug labeling Moderate Impact assessment initiated
08/04/2026 EMA Newsletter Safety alert on excipient change requirements Critical Immediate review required
08/04/2026 PMDA Update Publication of revised clinical trial data reporting standards Informational Logged for reference

Annexure-2: Regulatory News Triage Assessment Form

Purpose: To document detailed evaluation and risk assessment of triaged regulatory news items, including potential impacts and recommended actions.

News Item No. Date Evaluated News Summary Impact Assessment Recommended Action Reviewer Comments
002 08/04/2026 Safety alert on excipient change requirements May require updated product documentation and submission Initiate internal cross-functional review and update regulatory filings Urgent coordination needed with Manufacturing and Quality

Annexure-3: Communication Template for Regulatory News Dissemination

Purpose: To standardize the format for communicating evaluated regulatory news to relevant stakeholders ensuring clarity and traceability.

See also  SOP for Coordination Between Regulatory QA CMC and Clinical Teams
Date: 08/04/2026
To: Quality Assurance, Manufacturing, Regulatory Affairs, Safety
From: Regulatory Affairs Manager
Subject: Critical Regulatory News Alert: Safety Alert on Excipient Change Requirements
Summary: Regulatory authorities have issued a safety alert requiring updates to excipient-related product information.
Impact: Potential changes to product labeling and regulatory submissions may be necessary to maintain compliance.
Actions Required:
  • Initiate internal cross-functional assessment
  • Update relevant documentation
  • Prepare regulatory submissions as applicable
Contact for Queries: Regulatory Intelligence Team
Remarks:

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
09/04/2026 1.0 Initial issue New SOP creation